The peptide does not appear to significantly affect glucose metabolism or insulin sensitivity in the way that full-length growth hormone does - growth hormone causes insulin resistance through various mechanisms, whereas AOD9604 has been reported to be neutral or possibly even beneficial for insulin sensitivity
Data from the CT388-103 and CT388-104 studies suggest that enicepatide could become an important standalone medicine and a key backbone for potential combination therapies within Roches cardiometabolic pipeline
it's packed with nutrients, fiber, and healthy fats, which keeps me feeling full and satisfied for hours, a major plus for anyone managing their appetite on GLP-1
I have many veterans who have started GLP-1's, however haven't seen this trend yet
Its been studied in horses, rodents, and humans, with promising results in wound closure, tendon repair, and cardiac tissue recovery